Antibodies that specifically binds to human TNFalpha； Pharmaceutical composition that comprises Nucleic Acid Molecule； isolated； vector； method to reduce the tendency to Aggregation of Antibody.
The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.ANTICUERPOS QUE SE UNE ESPECIFICAMENTE A TNFALFA HUMANO； COMPOSICION FARMACÉUTICA QUE LA COMPRENDE； MOLÉCULA DE ÁCIDO NUCLEICO AISLADO； VECTOR； METODO PARA REDUCIR LA TENDENCIA A LA AGREGACIÓN DE UN ANTICUERPO.
